WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, August 31, 2006

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L5	L4 and synthetic	17
☐	L4	L3 and carrier adj protein	18
☐	L3	L2 and conjugated	57
☐	L2	L1 and solid adj phase	80
☐	L1	424/228.1.ICLS.	141

END OF SEARCH HISTORY

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1648BQL

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27  New STN AnaVist pricing effective March 1, 2006
 NEWS  4  APR 04  STN AnaVist $500 visualization usage credit offered
 NEWS  5  MAY 10  CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  6  MAY 11  KOREAPAT updates resume
 NEWS  7  MAY 19  Derwent World Patents Index to be reloaded and enhanced
 NEWS  8  MAY 30  IPC 8 Rolled-up Core codes added to CA/CAplus and
                  USPATFULL/USPAT2
 NEWS  9  MAY 30  The F-Term thesaurus is now available in CA/CAplus
 NEWS 10  JUN 02  The first reclassification of IPC codes now complete in
                  INPADOC
 NEWS 11  JUN 26  TULSA/TULSA2 reloaded and enhanced with new search and
                  and display fields
 NEWS 12  JUN 28  Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 13  JUl 11  CHEMSAFE reloaded and enhanced
 NEWS 14  JUl 14  FSTA enhanced with Japanese patents
 NEWS 15  JUl 19  Coverage of Research Disclosure reinstated in DWPI
 NEWS 16  AUG 09  INSPEC enhanced with 1898-1968 archive
 NEWS 17  AUG 28  ADISCTI Reloaded and Enhanced
 NEWS 18  AUG 30  CA(SM)/CAplus(SM) Austrian patent law changes

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:23:56 ON 31 AUG 2006

=> file caplus biosis
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
```

```
FULL ESTIMATED COST                                    0.21        0.21

FILE 'CAPLUS' ENTERED AT 08:24:12 ON 31 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 08:24:12 ON 31 AUG 2006
Copyright (c) 2006 The Thomson Corporation

=> HCV (s) conjugat3
 75% OF LIMIT FOR TOTAL ANSWERS REACHED
L1     9357874 3

=> solid (s) phase
L2      222835 SOLID (S) PHASE

=> carrier (w) protein
L3       14905 CARRIER (W) PROTEIN

=> L1 and l3
L4        4345 L1 AND L3

=> combinantion
L5          11 COMBINANTION

=> L4 and L2
L6          85 L4 AND L2

=> core and L6
L7           0 CORE AND L6

=> Core (w) antigen
L8        4778 CORE (W) ANTIGEN

=> L8 and L6
L9           0 L8 AND L6

=> L8 and L1
L10       1207 L8 AND L1

=> sensitiz3
SYSTEM LIMITS EXCEEDED - SEARCH ENDED
The search profile you entered was too complex or gave too many
answers.  Simplify or subdivide the query and try again.  If you have
exceeded the answer limit, enter DELETE HISTORY at an arrow prompt
(=>) to remove all previous answers sets and begin at L1.  Use the
SAVE command to store any important profiles or answer sets before
using DELETE HISTORY.

=> D history

     (FILE 'HOME' ENTERED AT 08:23:56 ON 31 AUG 2006)

     FILE 'CAPLUS, BIOSIS' ENTERED AT 08:24:12 ON 31 AUG 2006
L1      9357874 3
L2       222835 SOLID (S) PHASE
L3        14905 CARRIER (W) PROTEIN
L4         4345 L1 AND L3
L5           11 COMBINANTION
L6           85 L4 AND L2
L7            0 CORE AND L6
L8         4778 CORE (W) ANTIGEN
```

```
L9             0 L8 AND L6
L10         1207 L8 AND L1

=> NS3 and L10
L11           59 NS3 AND L10

=> NS5 and L11
L12           33 NS5 AND L11

=> conjugated and L12
L13            0 CONJUGATED AND L12

=> synthetic and L12
L14            5 SYNTHETIC AND L12

=> D L14 IBIB ABS 1-5

L14  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:287791  CAPLUS
DOCUMENT NUMBER:          140:320023
TITLE:                    DNA vaccine comprising plasmids encoding core-E1-E2,
                          NS3-NS4 and NS5 genes for enhancing
                          protective immunity to hepatitis C virus
INVENTOR(S):              Sung, Young Chul; Youn, Jin-Won; Yang, Se-Hwan; Park,
                          Su-Hyung; Lee, Chang Geun
PATENT ASSIGNEE(S):       Genexine Inc., S. Korea; Postech Foundation; Dong-A
                          Pharm. Co., Ltd.; Daewoong Co., Ltd.; Posco
SOURCE:                   PCT Int. Appl., 165 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2004028563         A1    20040408    WO 2003-KR1951           20030924
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     KR 2004027247         A     20040401    KR 2002-68496            20021106
     AU 2003263653         A1    20040419    AU 2003-263653           20030924
     US 2005287117         A1    20051229    US 2005-528644           20050318
PRIORITY APPLN. INFO.:                       KR 2002-58712        A   20020927
                                             KR 2002-68496        A   20021106
                                             WO 2003-KR1951       W   20030924
AB   The present invention relates to a vaccine enhancing the protective
     immunity to Hepatitis C virus using plasmid DNA recombinant adenovirus,
     more particularly to a vaccine consisting of Δ core-E1-E2 expressing
     DNA vaccine, nonstructural protein NS3 and NS4 expressing DNA
     vaccine, nonstructural protein NS5 expressing DNA vaccine and
     recombinant adenovirus vaccine, and method for administration of the
     vaccine by priming with the DNA vaccines described above and boosting with
     the recombinant adenovirus vaccine thereby enhancing the protective
     immunity to Hepatitis C virus.
REFERENCE COUNT:          4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
```

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:633162 CAPLUS
DOCUMENT NUMBER: 139:178676
TITLE: Methods for the simultaneous detection of hcv antigens and hcv antibodies
INVENTOR(S): Shah, Dinesh O.; Dawson, George J.; Muerhoff, A. Scott; Jiang, Lily; Gutierrez, Robin A.; Leary, Thomas P.; Desai, Suresh; Stewart, James L.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 891,983.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003152948	A1	20030814	US 2002-173480	20020617
US 6727092	B2	20040427		
US 2003108858	A1	20030612	US 2001-891983	20010626
CA 2450710	AA	20030109	CA 2002-2450710	20020624
WO 2003002749	A2	20030109	WO 2002-US19958	20020624
WO 2003002749	A3	20030710		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1412538	A2	20040428	EP 2002-746647	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005518186	T2	20050623	JP 2003-509110	20020624
US 2004185436	A1	20040923	US 2004-753910	20040107
US 6855809	B2	20050215		

PRIORITY APPLN. INFO.:

US 2001-891983	A2	20010626
US 2002-173480	A	20020617
WO 2002-US19958	W	20020624

AB The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (HCV) antigens as well as antibodies produced in response to HCV antigens. Furthermore, the subject invention allows one to detect antigens in the early, acute stage of infection, even prior to the development of antibodies, thereby allowing for early detection of infected blood and blood products, thus improving the safety of the blood supply. The method allows the detection of the antigen or the antibody, or both, in a single assay. Antigens are detected with immobilized antibodies and antibodies are detected with immobilized antigens. After incubating the immobilized agents with a test sample, they are then incubated with labeled antibodies. Bound antigen is detected with an antibody to the antigen. Bound antibody is detected with a mouse monoclonal antibody to a human antibody, typically IgG.

L14 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:124651 CAPLUS
DOCUMENT NUMBER: 135:209508
TITLE: Diagnostic potential of an enzyme immunoassay system for evaluation of the spectrum of antibodies to hepatitis C structural and nonstructural antigens
AUTHOR(S): Pimenov, V. K.; Afanas'ev, A. Yu.; Kolobov, A. A.; Zubov, S. V.; Dobrotina, N. A.; Novikov, V. V.
CORPORATE SOURCE: Nizhegorod. Gos. Univ. im. N. I. Lobachevskogo, Nizhniy Novgorod, Russia

SOURCE: Voprosy Virusologii (2000), 45(6), 44-47
CODEN: VVIRAT; ISSN: 0507-4088
PUBLISHER: Meditsina
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB A new enzyme immunoassay EIA-HCV-Spectra test system constructed on the base of recombinant proteins and synthetic peptides allows sep. detection of antibodies to E1/E2, core, NS3, NS4, and NS5 antigens of hepatitis C virus (HCV). The system is highly specific and more sensitive than the test systems used in screening studies, which allows its use as a final test for antiHCV antibodies. Antibodies to various HCV antigens were analyzed using this test system in patients with acute and chronic hepatitis C and asymptomatic donors with antiHCV. In acute hepatitis C during the first-second week after clin. attis C and asymptomatic donors with antiHCV. In acute hepatitis C during the first and second week after clin. manifestation, antibodies to nonstructural virus proteins are detected 3-4 times less often than in chronic hepatitis C. Acute hepatitis C is characterized by the presence of antibodies only to core antigen (66%). In chronic condition combinations of antibodies to structural and nonstructural HCV antigens predominate: core + NS4, core + NS3 + NS4, core + NS3 + NS5, core + NS4 + NS5, and core + NS3 + NS4 + NS5. In asymptomatic donors with antiHCV and in patients with chronic hepatitis C the spectra of antibodies were similar in 45.7% cases.

L14 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:54036 CAPLUS
DOCUMENT NUMBER: 126:73782
TITLE: Unprocessed core-envelope fusion protein and nonstructural protein for the diagnosis of and vaccination against hepatitis C virus
INVENTOR(S): Liao, Jaw-Ching; Wang, Cheng-Nan
PATENT ASSIGNEE(S): Bionova Corporation, USA; Liao, Jaw-Ching; Wang, Cheng-Nan
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9637606	A1	19961128	WO 1996-US7378		19960522
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI					
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN					
ZA 9604094	A	19961203	ZA 1996-4094		19960522
AU 9659243	A1	19961211	AU 1996-59243		19960522
PRIORITY APPLN. INFO.:			US 1995-447276	A	19950522
			WO 1996-US7378	W	19960522

AB The unprocessed core protein region initially translated from the genome of hepatitis C virus (HCV) contains epitopic configurations that are not retained in the processed proteins. In particular, the core protein loses an epitopic configuration upon processing at the cleavage site between the genomic region (e.g., gene) encoding the core protein and the genomic region encoding the adjacent envelope region. The unprocessed epitopic configuration of the core region provides an improved ability to detect the presence of HCV, or antibodies to HCV, in a sample, including an

unpurified sample or a sample of very small volume (which can be particularly helpful when testing a sample from an infant or other person having very little blood (or other suitable material) available for testing). Combining the unprocessed core region with a nonstructural protein (such as an NS5 or an NS3-NS4 fusion) results in a synergistic effect that greatly enhances the already improved sensitivity and specificity provided by the unprocessed core region. The unprocessed epitopic configuration of the core region also provides an improved ability to induce an immune response upon administration of the core region into an animal. Recombinant methods are described for the preparation of a cloned DNA mol. (EN-80-2) derived from the HCV core and envelope regions and for a clone (EN-80-1) encoding the NS5 nonstructural protein.

L14 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 2001:141740 BIOSIS
DOCUMENT NUMBER: PREV200100141740
TITLE: Diagnostic potentialities of enzyme immunoassay system for evaluation of the spectrum of antibodies to hepatitis C structural and nonstructural antigens.
AUTHOR(S): Pimenov, V. K.; Afanasyev, A. Yu.; Kolobov, A. A.; Zubov, S. V.; Dobrotina, N. A.; Novikov, V. V.
SOURCE: Voprosy Virusologii, (November-December, 2000) No. 6, pp. 44-47. print.
CODEN: VVIRAT. ISSN: 0507-4088.
DOCUMENT TYPE: Article
LANGUAGE: Russian
ENTRY DATE: Entered STN: 21 Mar 2001
Last Updated on STN: 15 Feb 2002

AB A new enzyme immunoassay EIA-HCV-Spectr test system constructed on the base of recombinant proteins and synthetic peptides allows separate detection of antibodies to E1/E2, core, HS3, NS4, and NS5 antigens of hepatitis C virus (HCV). The system is highly specific and more sensitive than the test systems used in screening studies, which allows its use as a final test for antiHCV antibodies. Antibodies to various HCV antigens were analyzed using this test system in patients with acute and chronic hepatitis C and asymptomatic donors with antiHCV. In acute hepatitis C during the first-second week after clinical manifestation, antibodies to nonstructural virus proteins are detected 3-4 times less often than in chronic hepatitis C. Acute hepatitis C is characterized by the presence of antibodies only to core antigen (68%). In chronic condition combinations of antibodies to structural and nonstructural HCV antigens predominate: core+NS4, core+NS3+NS4, core+NS3+NS5, core+NS4+NS5, and core+NS3+NS4+NS5. In asymptomatic donors with antiHCV and in patients with chronic hepatitis C the spectra of antibodies were similar in 45.7% cases.

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1648BQL

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27   New STN AnaVist pricing effective March 1, 2006
 NEWS  4  APR 04   STN AnaVist $500 visualization usage credit offered
 NEWS  5  MAY 10   CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  6  MAY 11   KOREAPAT updates resume
 NEWS  7  MAY 19   Derwent World Patents Index to be reloaded and enhanced
 NEWS  8  MAY 30   IPC 8 Rolled-up Core codes added to CA/CAplus and
                   USPATFULL/USPAT2
 NEWS  9  MAY 30   The F-Term thesaurus is now available in CA/CAplus
 NEWS 10  JUN 02   The first reclassification of IPC codes now complete in
                   INPADOC
 NEWS 11  JUN 26   TULSA/TULSA2 reloaded and enhanced with new search and
                   and display fields
 NEWS 12  JUN 28   Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 13  JUl 11   CHEMSAFE reloaded and enhanced
 NEWS 14  JUl 14   FSTA enhanced with Japanese patents
 NEWS 15  JUl 19   Coverage of Research Disclosure reinstated in DWPI
 NEWS 16  AUG 09   INSPEC enhanced with 1898-1968 archive
 NEWS 17  AUG 28   ADISCTI Reloaded and Enhanced
 NEWS 18  AUG 30   CA(SM)/CAplus(SM) Austrian patent law changes

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:23:56 ON 31 AUG 2006

=> file caplus biosis
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
```

```
FULL ESTIMATED COST                                    0.21        0.21

FILE 'CAPLUS' ENTERED AT 08:24:12 ON 31 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 08:24:12 ON 31 AUG 2006
Copyright (c) 2006 The Thomson Corporation

=> HCV (s) conjugat3
 75% OF LIMIT FOR TOTAL ANSWERS REACHED
L1     9357874 3

=> solid (s) phase
L2      222835 SOLID (S) PHASE

=> carrier (w) protein
L3       14905 CARRIER (W) PROTEIN

=> L1 and l3
L4        4345 L1 AND L3

=> combinantion
L5          11 COMBINANTION

=> L4 and L2
L6          85 L4 AND L2

=> core and L6
L7           0 CORE AND L6

=> Core (w) antigen
L8        4778 CORE (W) ANTIGEN

=> L8 and L6
L9           0 L8 AND L6

=> L8 and L1
L10       1207 L8 AND L1

=> sensitiz3
SYSTEM LIMITS EXCEEDED - SEARCH ENDED
The search profile you entered was too complex or gave too many
answers.  Simplify or subdivide the query and try again.  If you have
exceeded the answer limit, enter DELETE HISTORY at an arrow prompt
(=>) to remove all previous answers sets and begin at L1.  Use the
SAVE command to store any important profiles or answer sets before
using DELETE HISTORY.

=> D history

     (FILE 'HOME' ENTERED AT 08:23:56 ON 31 AUG 2006)

     FILE 'CAPLUS, BIOSIS' ENTERED AT 08:24:12 ON 31 AUG 2006
L1      9357874 3
L2       222835 SOLID (S) PHASE
L3        14905 CARRIER (W) PROTEIN
L4         4345 L1 AND L3
L5           11 COMBINANTION
L6           85 L4 AND L2
L7            0 CORE AND L6
L8         4778 CORE (W) ANTIGEN
```

```
L9             0 L8 AND L6
L10         1207 L8 AND L1

=> NS3 and L10
L11           59 NS3 AND L10

=> NS5 and L11
L12           33 NS5 AND L11

=> conjugated and L12
L13            0 CONJUGATED AND L12

=> synthetic and L12
L14            5 SYNTHETIC AND L12

=> D L14 IBIB ABS 1-5

L14  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:287791  CAPLUS
DOCUMENT NUMBER:          140:320023
TITLE:                    DNA vaccine comprising plasmids encoding core-E1-E2,
                          NS3-NS4 and NS5 genes for enhancing
                          protective immunity to hepatitis C virus
INVENTOR(S):              Sung, Young Chul; Youn, Jin-Won; Yang, Se-Hwan; Park,
                          Su-Hyung; Lee, Chang Geun
PATENT ASSIGNEE(S):       Genexine Inc., S. Korea; Postech Foundation; Dong-A
                          Pharm. Co., Ltd.; Daewoong Co., Ltd.; Posco
SOURCE:                   PCT Int. Appl., 165 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2004028563         A1    20040408    WO 2003-KR1951           20030924
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     KR 2004027247         A     20040401    KR 2002-68496            20021106
     AU 2003263653         A1    20040419    AU 2003-263653           20030924
     US 2005287117         A1    20051229    US 2005-528644           20050318
PRIORITY APPLN. INFO.:                       KR 2002-58712         A  20020927
                                             KR 2002-68496         A  20021106
                                             WO 2003-KR1951        W  20030924
AB   The present invention relates to a vaccine enhancing the protective
     immunity to Hepatitis C virus using plasmid DNA recombinant adenovirus,
     more particularly to a vaccine consisting of Δ core-E1-E2 expressing
     DNA vaccine, nonstructural protein NS3 and NS4 expressing DNA
     vaccine, nonstructural protein NS5 expressing DNA vaccine and
     recombinant adenovirus vaccine, and method for administration of the
     vaccine by priming with the DNA vaccines described above and boosting with
     the recombinant adenovirus vaccine thereby enhancing the protective
     immunity to Hepatitis C virus.
REFERENCE COUNT:          4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
```

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:633162 CAPLUS
DOCUMENT NUMBER: 139:178676
TITLE: Methods for the simultaneous detection of hcv antigens and hcv antibodies
INVENTOR(S): Shah, Dinesh O.; Dawson, George J.; Muerhoff, A. Scott; Jiang, Lily; Gutierrez, Robin A.; Leary, Thomas P.; Desai, Suresh; Stewart, James L.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 891,983.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003152948	A1	20030814	US 2002-173480	20020617
US 6727092	B2	20040427		
US 2003108858	A1	20030612	US 2001-891983	20010626
CA 2450710	AA	20030109	CA 2002-2450710	20020624
WO 2003002749	A2	20030109	WO 2002-US19958	20020624
WO 2003002749	A3	20030710		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1412538	A2	20040428	EP 2002-746647	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2005518186	T2	20050623	JP 2003-509110	20020624
US 2004185436	A1	20040923	US 2004-753910	20040107
US 6855809	B2	20050215		

PRIORITY APPLN. INFO.:
US 2001-891983 A2 20010626
US 2002-173480 A 20020617
WO 2002-US19958 W 20020624

AB The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (HCV) antigens as well as antibodies produced in response to HCV antigens. Furthermore, the subject invention allows one to detect antigens in the early, acute stage of infection, even prior to the development of antibodies, thereby allowing for early detection of infected blood and blood products, thus improving the safety of the blood supply. The method allows the detection of the antigen or the antibody, or both, in a single assay. Antigens are detected with immobilized antibodies and antibodies are detected with immobilized antigens. After incubating the immobilized agents with a test sample, they are then incubated with labeled antibodies. Bound antigen is detected with an antibody to the antigen. Bound antibody is detected with a mouse monoclonal antibody to a human antibody, typically IgG.

L14 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:124651 CAPLUS
DOCUMENT NUMBER: 135:209508
TITLE: Diagnostic potential of an enzyme immunoassay system for evaluation of the spectrum of antibodies to hepatitis C structural and nonstructural antigens
AUTHOR(S): Pimenov, V. K.; Afanas'ev, A. Yu.; Kolobov, A. A.; Zubov, S. V.; Dobrotina, N. A.; Novikov, V. V.
CORPORATE SOURCE: Nizhegorod. Gos. Univ. im. N. I. Lobachevskogo, Nizhniy Novgorod, Russia

SOURCE: Voprosy Virusologii (2000), 45(6), 44-47
CODEN: VVIRAT; ISSN: 0507-4088
PUBLISHER: Meditsina
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB A new enzyme immunoassay EIA-HCV-Spectra test system constructed on the base of recombinant proteins and synthetic peptides allows sep. detection of antibodies to E1/E2, core, NS3, NS4, and NS5 antigens of hepatitis C virus (HCV). The system is highly specific and more sensitive than the test systems used in screening studies, which allows its use as a final test for antiHCV antibodies. Antibodies to various HCV antigens were analyzed using this test system in patients with acute and chronic hepatitis C and asymptomatic donors with antiHCV. In acute hepatitis C during the first-second week after clin. attis C and asymptomatic donors with antiHCV. In acute hepatitis C during the first and second week after clin. manifestation, antibodies to nonstructural virus proteins are detected 3-4 times less often than in chronic hepatitis C. Acute hepatitis C is characterized by the presence of antibodies only to core antigen (66%). In chronic condition combinations of antibodies to structural and nonstructural HCV antigens predominate: core + NS4, core + NS3 + NS4, core + NS3 + NS5, core + NS4 + NS5, and core + NS3 + NS4 + NS5. In asymptomatic donors with antiHCV and in patients with chronic hepatitis C the spectra of antibodies were similar in 45.7% cases.

L14 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:54036 CAPLUS
DOCUMENT NUMBER: 126:73782
TITLE: Unprocessed core-envelope fusion protein and nonstructural protein for the diagnosis of and vaccination against hepatitis C virus
INVENTOR(S): Liao, Jaw-Ching; Wang, Cheng-Nan
PATENT ASSIGNEE(S): Bionova Corporation, USA; Liao, Jaw-Ching; Wang, Cheng-Nan
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9637606	A1	19961128	WO 1996-US7378	19960522
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
ZA 9604094	A	19961203	ZA 1996-4094	19960522
AU 9659243	A1	19961211	AU 1996-59243	19960522
PRIORITY APPLN. INFO.:			US 1995-447276 A	19950522
			WO 1996-US7378 W	19960522

AB The unprocessed core protein region initially translated from the genome of hepatitis C virus (HCV) contains epitopic configurations that are not retained in the processed proteins. In particular, the core protein loses an epitopic configuration upon processing at the cleavage site between the genomic region (e.g., gene) encoding the core protein and the genomic region encoding the adjacent envelope region. The unprocessed epitopic configuration of the core region provides an improved ability to detect the presence of HCV, or antibodies to HCV, in a sample, including an

unpurified sample or a sample of very small volume (which can be particularly helpful when testing a sample from an infant or other person having very little blood (or other suitable material) available for testing). Combining the unprocessed core region with a nonstructural protein (such as an NS5 or an NS3-NS4 fusion) results in a synergistic effect that greatly enhances the already improved sensitivity and specificity provided by the unprocessed core region. The unprocessed epitopic configuration of the core region also provides an improved ability to induce an immune response upon administration of the core region into an animal. Recombinant methods are described for the preparation of a cloned DNA mol. (EN-80-2) derived from the HCV core and envelope regions and for a clone (EN-80-1) encoding the NS5 nonstructural protein.

L14 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 2001:141740 BIOSIS
DOCUMENT NUMBER: PREV200100141740
TITLE: Diagnostic potentialities of enzyme immunoassay system for evaluation of the spectrum of antibodies to hepatitis C structural and nonstructural antigens.
AUTHOR(S): Pimenov, V. K.; Afanasyev, A. Yu.; Kolobov, A. A.; Zubov, S. V.; Dobrotina, N. A.; Novikov, V. V.
SOURCE: Voprosy Virusologii, (November-December, 2000) No. 6, pp. 44-47. print.
CODEN: VVIRAT. ISSN: 0507-4088.
DOCUMENT TYPE: Article
LANGUAGE: Russian
ENTRY DATE: Entered STN: 21 Mar 2001
Last Updated on STN: 15 Feb 2002

AB A new enzyme immunoassay EIA-HCV-Spectr test system constructed on the base of recombinant proteins and synthetic peptides allows separate detection of antibodies to E1/E2, core, HS3, NS4, and NS5 antigens of hepatitis C virus (HCV). The system is highly specific and more sensitive than the test systems used in screening studies, which allows its use as a final test for antiHCV antibodies. Antibodies to various HCV antigens were analyzed using this test system in patients with acute and chronic hepatitis C and asymptomatic donors with antiHCV. In acute hepatitis C during the first-second week after clinical manifestation, antibodies to nonstructural virus proteins are detected 3-4 times less often than in chronic hepatitis C. Acute hepatitis C is characterized by the presence of antibodies only to core antigen (68%). In chronic condition combinations of antibodies to structural and nonstructural HCV antigens predominate: core+NS4, core+ NS3+NS4, core+NS3+NS5, core+NS4+NS5, and core+NS3+NS4+NS5. In asymptomatic donors with antiHCV and in patients with chronic hepatitis C the spectra of antibodies were similar in 45.7% cases.